Xenetic Biosciences, Inc. filed a Current Report on Form 8-K on November 13, 2026, announcing third-quarter financial results for the period ended September 30, 2026, and providing strategic business updates including details related to a proposed share exchange transaction with Santersus AG.
Key Highlights
- Quarterly results announced: The company issued a press release on November 13, 2026, covering results for the three months ended September 30, 2026.
- Proposed transaction disclosed: The filing references a proposed share exchange transaction with Santersus AG, including anticipated combined company listing on Nasdaq after closing.
- Soliciting material checked: The filing is checked as soliciting material pursuant to Rule 14a-12 under the Exchange Act.
- DNase clinical study referenced: Forward-looking statements mention an investigator-initiated clinical study evaluating systemic recombinant human DNase in combination with anti-CD19 CAR T-cell therapy in patients with large B-cell lymphoma at the Ichilov Center in Israel.
- Exhibit 99.1 attached: The full text of the press release is furnished as Exhibit 99.1 and incorporated by reference into Item 2.02.
- Furnished, not filed: The information in Item 2.02 and Exhibit 99.1 "shall not be deemed 'filed' for purposes of Section 18 of the Securities Exchange Act of 1934, as amended," according to the filing.
Xenetic Biosciences Reports Q3 2026 Results While Advancing Santersus Share Exchange
Xenetic Biosciences, Inc. (NASDAQ:XBIO), headquartered at 945 Concord Street, Framingham, Massachusetts, filed an 8-K with the Securities and Exchange Commission on November 13, 2026. According to the filing, the company issued a press release on that same date announcing results for the three months ended September 30, 2026, and highlighting what the company described as "strategic business updates." The press release is furnished as Exhibit 99.1 and is incorporated into Item 2.02 of the report by reference.
The filing discloses a proposed share exchange transaction with Santersus AG, referred to as the "Proposed Transaction." Forward-looking statements in the 8-K address the structure, timing, and completion of that transaction, including the anticipated listing of the combined company on Nasdaq following closing, the expected ownership structure, and the combined company's development programs. The filing also references an investigator-initiated clinical study at the Ichilov Center in Israel evaluating systemic recombinant human DNase in combination with anti-CD19 CAR T-cell therapy in patients with large B-cell lymphoma, as well as the company's stated focus on advancing a systemic DNase program for pancreatic carcinoma and locally advanced or metastatic solid tumors.
The company noted that the forward-looking statements in the filing and the accompanying press release "are intended to be subject to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995." The filing enumerates multiple risk factors associated with the Proposed Transaction, including the risk that stockholder approval may not be obtained, uncertainties around exchange ratio adjustments that could affect ownership percentages, and the risk that the combined company may not maintain compliance with Nasdaq listing requirements following closing. The filing expressly states that the information in Item 2.02 is furnished and "shall not be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, except as shall be expressly set forth by specific reference in such filing."
What Was Disclosed
Xenetic Biosciences filed an 8-K on November 13, 2026, furnishing a press release covering Q3 2026 results for the period ended September 30, 2026, and providing updates on the proposed share exchange transaction with Santersus AG, along with associated forward-looking statements and risk factors.



Please wait processing your request...